Core--Vector

核心--向量

• 批准号: 7410006
• 负责人: Douglas M McCarty
• 金额: $ 14.15万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2009-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7410006
• 关键词: Capsid; Cells; Chimera organism; Core Facility; Cystic Fibrosis; Development; Feasibility Studies; Genes; Goals; Growth; Laboratories; Metabolic Diseases; Methods; Operative Surgical Procedures; Paramyxovirus; Plasmids; Play; Preparation; Production; Research; Research Personnel; Respiratory syncytial virus; Role; Serotyping; Services; Small Interfering RNA; Technology; Time; Tissues; Viral Vector; adeno-associated viral vector; gene therapy; helper-dependent adenoviral vector; interest; new technology; novel; parainfluenza virus; programs; vector

The Viral Vector Core Facility is an integral component of the UNC Gene Therapy Center. It has been in operation for over 8 years and has maintained an exponential level of production growth over this time. This growth has been accomplished by rapid incorporation of new technological developments as they become available, and by a commitment to making the proceeds of these technologies as widely accessible to researchers as possible. The pursuit of these goals will continue within the proposed research program. Among the new technologies and services to be added to the Vector Core will be the production of helper-dependent adenovirus vectors (HD-Ad), chimeric capsid adeno-associated virus vectors (chAAV), double-strand (or self-complementary) adeno-associated virus vectors (dsAAV), paramyxovirus vectors, and large-scale plasmid preparations to facilitate the production of experimental laboratory-scale stocks of viral vectors. Each of these services will dovetail with the specific needs and research interests of the MTCC investigators and their cystic fibrosis and metabolic disease research programs. Some of these new services will also play an important supporting role in the proposed pilot and feasibility studies, i.e., production of chAAV (McCarty, P.I.) and paramyxovirus vectors (Pickles, P.I.).

病毒载体核心设施是基因治疗中心的一个组成部分。它已经运行了8年多，并在此期间保持了指数级的生产增长。这一增长是通过迅速吸收新的技术发展，并通过致力于使研究人员尽可能广泛地获得这些技术的收益来实现的。这些目标的追求将在拟议的研究计划中继续进行。新技术和服务将添加到载体核心中，包括辅助依赖性腺病毒载体（HD-Ad），嵌合衣壳腺相关病毒载体（chAAV），双链（或自身互补）腺相关病毒载体（dsAAV），副粘病毒载体和大规模质粒制备的生产，以促进实验室规模病毒载体库存的生产。这些服务中的每一项都将与MTCC研究人员及其囊性纤维化和代谢性疾病研究计划的具体需求和研究兴趣相吻合。其中一些新服务也将在拟议的试验和可行性研究中发挥重要的支持作用，即，chAAV的产生（McCarty，P.I.）和副粘病毒载体（Pickles，P.I.）。